Hey, guys. I dug up two studies–which I feel represent a good chunk of the important info–on CLA. Specifically, these two studies point out important things to consider when supplementing your nutritional program with CLA. The two highlights are:
- Total dosage of Conjugated Linoleic Acid. That is, not the total number of capsules you plan on taking, as that is not representative of the total CLA you will be ingesting. Find the concentration of CLA in each cap to determine the number of capsules you need daily.
- The specific form/isomer of CLA supplemented with. One isomer will prove absolutely useless, whilst the other will boast some potent effects.
In both cases, the manufacturer is important. I know that Tonalin is well-respected one and would recommend it.
Here ya go, boys.
Conjugated Linoleic Acid Reduces Body Fat Mass in Overweight and Obese Humans
Henrietta Blankson, Jacob A. Stakkestad*, Hans *ertun, Erling Thom, Jan Wadstein and Ola Gudmundsen
Conjugated linoleic acid (CLA) has been shown to reduce body fat mass (BFM) in animals. To investigate the dose-response relationships of conjugated linoleic acid with regard to BFM in humans, a randomized, double-blind study including 60 overweight or obese volunteers (body mass index 25?35 kg/m2) was performed. The subjects were divided into five groups receiving placebo (9 g olive oil), 1.7, 3.4, 5.1 or 6.8 g conjugated linoleic acid per day for 12 wk, respectively. Dual-energy X-ray absorptiometry was used to measure body composition [measurements at wk 0 (baseline), 6 and 12]. Of the 60 subjects, 47 completed the study. Eight subjects withdrew from the study due to adverse events; however, no differences among treatment groups were found regarding adverse events. Repeated-measures analysis showed that a significantly higher reduction in BFM was found in the conjugated linoleic acid groups compared with the placebo group (P = 0.03). The reduction of body fat within the groups was significant for the 3.4 and 6.8 g CLA groups (P = 0.05 and P = 0.02, respectively). No significant differences among the groups were observed in lean body mass, body mass index, blood safety variables or blood lipids. The data suggest that conjugated linoleic acid may reduce BFM in humans and that no additional effect on BFM is achieved with doses > 3.4 g CLA/d.
The trans-10,cis-12 Isomer of Conjugated Linoleic Acid Downregulates Stearoyl-CoA Desaturase 1 Gene Expression in 3T3-L1 Adipocytes
Youngjin Choi*, Young-Cheul Kim*, Yong-Bong Han, Yeonhwa Park**, Michael W. Pariza** and James M. Ntambi*,
Conjugated linoleic acids (CLA) are a group of positional and geometric conjugated dienoic isomers of linoleic acid. The objective of this study was to determine the effects of the cis-9,trans-11 and trans-10,cis-12 isomers of conjugated linoleic acid on lipid composition and gene expression during the differentiation of mouse 3T3-L1 preadipocytes. Treatment of differentiating 3T3-L1 preadipocytes with trans-10,cis-12 conjugated linoleic acid (CLA) resulted in a dose-dependent decrease in the expression of the stearoyl-CoA desaturase 1 gene (SCD1). The expression of other adipocyte genes such as adipose P2 (aP2), fatty acid synthase (FAS), SCD2 and the key adipogenic transcription factors, peroxisome proliferator-activated receptor 2 (PPAR2) and CCAAT enhancer binding protein (C/EBP), remained elevated. Cells treated with trans-10,cis-12 CLA exhibited smaller lipid droplets, with reduced levels of the major monounsaturated fatty acids, palmitoleate and oleate. By contrast, the cis-9,trans-11 isomer did not alter adipocyte gene expression. Repression of the stearoyl-CoA desaturase gene expression in adipocytes by the trans-10,cis-12 isomer may contribute to the mechanisms by which CLA reduces body fat in mice.